Ovid Therapeutics

November is Epilepsy Awareness Month. ?? We’re honored to feature a conversation with Beth Dean, MBA, MPA, CEO of CURE Epilepsy. During CURE Epilepsy's SUDEP workshop hosted at our NYC office, we had the chance to speak with Beth about the importance of awareness, advocacy, and advancing research for the epilepsy community. Watch the video to hear her insights. #EpilepsyAwarenessMonth

Did you know that KCC2 is considered one of the most exciting therapeutic targets in neuroscience today? Directly activating KCC2 may open new avenues for potential treatments across a range of neurological conditions, including neuropsychiatric, neurodevelopmental and neurodegenerative diseases as well as pain, epilepsies and other seizure disorders. Learn more about KCC2 below and by viewing our KCC2 Download Day presentation: https://lnkd.in/eCBq8gFC

Raquel Cabo, Ovid’s SVP of Corporate Affairs and Commercial Strategy, is speaking at Fierce Life Sciences Events' Diversity, Equity & Inclusion Forum, centered on the theme “Embedding Equity: A Core Principle in Life Sciences and Healthcare.” Raquel will join a panel alongside other industry experts to explore how inclusive marketing, PR and advertising is transforming biopharma. She’ll highlight how Ovid’s commitment to patient-centered, culturally sensitive communications is not just a core value, but a driving force behind our corporate strategy. By embracing this approach, we’ve been able to build deep, meaningful connections with patient communities impacted by rare neurological conditions. Learn more and register for the event: https://lnkd.in/ei6YGDst #DEI #Biopharma

Thank you to everyone who joined us for KCC2 Download Day. Ovid’s Dr. Jeremy M. Levin, Meg Alexander, Amanda Banks, MD and Zhong Zhong, alongside thought leaders Jeff Noebels, Karl Kieburtz and Stephen Moss, dove into the transformative potential of directly activating KCC2 for a broad range of CNS conditions. We also shared progress and the science associated with our library of KCC2 direct activators currently in development, including our lead compound OV350. ? In case you missed it, check out highlights from the event below and watch the full webcast here: https://lnkd.in/eCBq8gFC

Join us on November 13 for an in-depth exploration of KCC2, a pivotal CNS target that regulates neuron excitability. Discover how KCC2 could revolutionize treatments for epilepsy, psychosis and mood disorders. During KCC2 Download Day Dr. Jeremy M. Levin, Meg Alexander, Amanda Banks, MD and Zhong Zhong, alongside thought leaders Jeff Noebels, Karl Kieburtz and Stephen Moss, will present Ovid’s library of KCC2 direct activators currently in development. They’ll also share insights into our progress towards submitting the first regulatory filing and initiating human studies for OV350, our leading compound. Don’t miss this opportunity to learn about the future of neurotherapeutics and the impact of KCC2 direct activation could have on neuropsychiatric, neurodevelopmental and neurodegenerative conditions. Register to join in person: https://lnkd.in/eGzQqw9X Register to join the virtual webcast: https://lnkd.in/eCBq8gFC

With Thanksgiving just around the corner, Rachel’s here to share a cozy, adaptive recipe: Butternut Squash Chili!?Watch as she walks us through each step, sharing practical tips for making cooking accessible and enjoyable for everyone.

We’re honored to welcome three recognized thought leaders in neurology and neuropharmacology to present at Ovid’s KCC2 Download Day next week. Stephen Moss, Jeff Noebels and Karl Kieburtz will discuss the biological functions, underlying mechanisms and therapeutic promise of directly activating KCC2. KCC2 is one of the most exciting novel pathways in neurology due to its role in modulating neuronal hyperexcitability and neuroinflammation, the root cause of many brain disorders. Join us on November 13 to explore the biological and therapeutic significance of KCC2 activation across a wide range of CNS conditions. Register to join in person: https://lnkd.in/eGzQqw9X Register to join the virtual webcast: https://lnkd.in/eCBq8gFC

We want to extend our congratulations to the TSC Alliance as they celebrate their 50th anniversary. This organization has been pivotal in improving the lives of those affected by tuberous sclerosis complex (TSC) and has significantly influenced the rare disease and epilepsy fields. ? Over the past five decades, the TSC Alliance has set a benchmark for patient advocacy, reshaping interactions with the FDA and enhancing strategies for clinical trials. Their commitment to fostering collaboration and informed engagement has empowered patients and redefined the landscape of advocacy. Last week, Ovidians Meg Alexander, Ashley Vogel, Sravanthi Cheekati and Naomi Shaw had the honor of attending the TSC Alliance gala, where they celebrated this incredible milestone and reflected on the profound legacy of advocacy and support the organization has built.? ? Here’s to the TSC Alliance – a true leader in patient advocacy and a remarkable force for change.?

On November 13, we’ll be hosting “KCC2 Download Day,” an event profiling our portfolio of direct activators of the potassium chloride co-transporter 2 (KCC2). KCC2 is one of the most promising biological targets in the brain and may be central to normalizing neuronal activity in a broad range of conditions including seizures, psychiatric and neurodegenerative disorders. Join Ovid leaders Dr. Jeremy M. Levin, Meg Alexander, Zhong Zhong and Amanda Banks, MD, neuropharmacologists and neurologists from Baylor, Tufts and Rochester universities as they delve into the biology, mechanistic relevance and therapeutic opportunity associated with directly activating KCC2. ? During the session, we’ll also share progress updates on our franchise of KCC2 direct activators, including our first program OV350. If you’d like to join us in person, please register here: https://lnkd.in/eGzQqw9X To register for the virtual webcast, follow this link: https://lnkd.in/eCBq8gFC ? Please RSVP though the link or at [email protected].

Great to see the valuable work that the National Organization for Rare Disorders is doing to help shape the future of rare disease treatments by uniting leaders in this space and fostering meaningful dialogue with patients and caregivers. This year’s Breakthrough Summit gathered 900+ attendees and focused on the theme ‘Equitable Access to Innovation,’ providing a valuable opportunity to share knowledge that aims to empower the 400 million people worldwide living with rare diseases. Thank you NORD for creating space for connection, learning, and partnership to advance research and treatments. Congratulations on a successful event! #NORDSummit